Unsolved mystery of Fas: mononuclear cells may have trouble dying in patients with Sjögren's syndrome.
Autoimmune disorders
B cells
CD95
CD95L
Fas
Fas Ligand
Monocytes
NSAIDs
Sjögren’s syndrome
T cells
Journal
BMC immunology
ISSN: 1471-2172
Titre abrégé: BMC Immunol
Pays: England
ID NLM: 100966980
Informations de publication
Date de publication:
23 Jun 2023
23 Jun 2023
Historique:
received:
24
01
2022
accepted:
01
06
2023
medline:
26
6
2023
pubmed:
24
6
2023
entrez:
23
6
2023
Statut:
epublish
Résumé
Patients with Sjögren's syndrome, like other patients with autoimmune disorders, display dysregulation in the function of their immune system. Fas and Fas Ligand (FasL) are among the dysregulated proteins. We studied Fas and FasL on IL-2Rα FasL was increased in patients' T and B cells while Fas was increased in patients' monocytes, T and B cells. No signs of increased apoptosis were found. sFas and sFasL in patients' serum were increased, although the increase in sFasL was not significant. We suspect an effect of non-steroidal anti-inflammatory therapy on B cells, explaining the decrease of the percentage Fas Mononuclear cells expressing IL-2Rα
Sections du résumé
BACKGROUND
BACKGROUND
Patients with Sjögren's syndrome, like other patients with autoimmune disorders, display dysregulation in the function of their immune system. Fas and Fas Ligand (FasL) are among the dysregulated proteins.
METHODS
METHODS
We studied Fas and FasL on IL-2Rα
RESULTS
RESULTS
FasL was increased in patients' T and B cells while Fas was increased in patients' monocytes, T and B cells. No signs of increased apoptosis were found. sFas and sFasL in patients' serum were increased, although the increase in sFasL was not significant. We suspect an effect of non-steroidal anti-inflammatory therapy on B cells, explaining the decrease of the percentage Fas
CONCLUSIONS
CONCLUSIONS
Mononuclear cells expressing IL-2Rα
Identifiants
pubmed: 37353767
doi: 10.1186/s12865-023-00544-5
pii: 10.1186/s12865-023-00544-5
pmc: PMC10288785
doi:
Substances chimiques
Annexin A5
0
Interleukin-2 Receptor alpha Subunit
0
bcl-2-Associated X Protein
0
fas Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12Informations de copyright
© 2023. The Author(s).
Références
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14476-81
pubmed: 10588730
J Immunol. 2012 Sep 15;189(6):2712-6
pubmed: 22888135
Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i67-i77
pubmed: 27940583
Science. 2010 Feb 26;327(5969):1098-102
pubmed: 20185720
Clin Exp Rheumatol. 2005 Nov-Dec;23(6):915
pubmed: 16396719
BMC Med. 2013 Mar 18;11:73
pubmed: 23497011
Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):157-164
pubmed: 29465360
J Exp Med. 1998 Jan 5;187(1):123-8
pubmed: 9419218
Immunity. 2016 Jul 19;45(1):209-23
pubmed: 27438772
Arthritis Rheum. 1999 Aug;42(8):1673-81
pubmed: 10446867
Science. 1994 Mar 25;263(5154):1759-62
pubmed: 7510905
Curr Opin Rheumatol. 2012 Mar;24(2):193-200
pubmed: 22249352
Mol Cell. 2005 Aug 19;19(4):475-84
pubmed: 16109372
EMBO J. 1995 Nov 15;14(22):5579-88
pubmed: 8521815
Arthritis Rheum. 1997 Jun;40(6):1126-9
pubmed: 9182923
Annu Rev Immunol. 2008;26:453-79
pubmed: 18062768
Biomed Res Int. 2017;2017:5981432
pubmed: 28326325
J Immunol. 1986 Jun 15;136(12):4503-8
pubmed: 3086434
Arthritis Res Ther. 2022 May 7;24(1):101
pubmed: 35526080
Mol Cell Biol. 1999 Mar;19(3):2098-108
pubmed: 10022897
Nat Genet. 2007 Sep;39(9):1074-82
pubmed: 17676041
Nat Immunol. 2000 Dec;1(6):469-74
pubmed: 11101867
J Rheumatol. 2000 Oct;27(10):2397-405
pubmed: 11036836
Immunology. 2006 Apr;117(4):548-57
pubmed: 16556269
Clin Biochem. 2007 Jan;40(1-2):6-10
pubmed: 17056024
J Biol Chem. 2007 Jan 19;282(3):1539-43
pubmed: 17135269
J Neurotrauma. 2006 May;23(5):604-16
pubmed: 16689665
Ann Intern Med. 1984 Dec;101(6):748-56
pubmed: 6437309
Rheumatol Int. 2009 Dec;30(2):181-5
pubmed: 19404646
Arthritis Res. 2002;4(6):353-9
pubmed: 12453311
Eur J Immunol. 1993 Mar;23(3):702-8
pubmed: 7680614
Front Immunol. 2016 Sep 27;7:382
pubmed: 27729910
Immunity. 1998 Jan;8(1):89-95
pubmed: 9462514
J Exp Med. 1997 Dec 15;186(12):2045-50
pubmed: 9396774
Lab Invest. 2001 Jan;81(1):95-105
pubmed: 11204278
J Biol Chem. 2006 Sep 29;281(39):29228-35
pubmed: 16880202
J Clin Invest. 2011 Mar;121(3):1174-90
pubmed: 21285513
Clin Exp Immunol. 2015 Jul;181(1):29-38
pubmed: 25736842
Dig Dis Sci. 2004 Sep;49(9):1518-25
pubmed: 15481331
Biochem Biophys Res Commun. 2015 Aug 7;463(4):1144-51
pubmed: 26102031
J Biol Chem. 1999 Jan 15;274(3):1541-8
pubmed: 9880531
Oral Dis. 2006 Nov;12(6):523-32
pubmed: 17054763
Proc Natl Acad Sci U S A. 1985 Sep;82(18):6281-5
pubmed: 3929255
J Oral Pathol Med. 2011 Oct;40(9):721-5
pubmed: 21521368
Trends Immunol. 2015 Dec;36(12):763-777
pubmed: 26572555
Immunity. 1999 Sep;11(3):281-8
pubmed: 10514006
Acta Reumatol Port. 2008 Jul-Sep;33(3):299-303
pubmed: 18846009
J Biol Chem. 2002 Mar 29;277(13):11345-51
pubmed: 11801595
Arthritis Rheum. 1996 Nov;39(11):1875-85
pubmed: 8912510
Oral Dis. 2005 Sep;11(5):274-87
pubmed: 16120113
J Rheumatol. 1993 Sep;20(9):1515-8
pubmed: 8164207
Endocr Metab Immune Disord Drug Targets. 2022;22(3):328-338
pubmed: 34370657
Nat Chem Biol. 2018 Dec;14(12):1079-1089
pubmed: 30429604
Cancer Res. 2013 Nov 15;73(22):6711-21
pubmed: 24072745
Rheumatology (Oxford). 2002 Mar;41(3):338-42
pubmed: 11934973
Transplant Proc. 2012 May;44(4):1139-42
pubmed: 22564647
Cell Death Differ. 2001 Sep;8(9):909-20
pubmed: 11526446
Curr Biol. 1999 Dec 16-30;9(24):1441-7
pubmed: 10607586
Immunity. 2013 Jan 24;38(1):13-25
pubmed: 23352221
Clin Exp Immunol. 2002 Jul;129(1):177-82
pubmed: 12100038
J Med Invest. 2003 Feb;50(1-2):32-8
pubmed: 12630566
Rheumatology (Oxford). 2019 Oct 1;58(10):1740-1745
pubmed: 31220315
Int J Mol Sci. 2018 Aug 11;19(8):
pubmed: 30103522
Arthritis Res Ther. 2011;13(5):R170
pubmed: 22018243
J Immunol. 2012 Jun 1;188(11):5785-91
pubmed: 22539790